Enclave Advisors LLC Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Enclave Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 31.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 392 shares of the biopharmaceutical company’s stock after acquiring an additional 94 shares during the quarter. Enclave Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $279,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. International Assets Investment Management LLC raised its stake in Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after buying an additional 879,916 shares during the last quarter. Worldquant Millennium Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $127,489,000. Icon Wealth Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals by 18,342.0% in the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock worth $79,874,000 after acquiring an additional 75,569 shares during the period. State Street Corp increased its position in Regeneron Pharmaceuticals by 1.3% during the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after acquiring an additional 61,277 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec lifted its holdings in Regeneron Pharmaceuticals by 40.2% in the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 194,625 shares of the biopharmaceutical company’s stock valued at $204,598,000 after acquiring an additional 55,828 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on REGN. JPMorgan Chase & Co. cut their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Citigroup reduced their target price on shares of Regeneron Pharmaceuticals from $895.00 to $795.00 and set a “neutral” rating for the company in a report on Tuesday, January 14th. Bank of America reiterated an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Finally, Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. One research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,015.38.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $687.80 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The company’s fifty day moving average price is $735.72 and its 200-day moving average price is $946.39. Regeneron Pharmaceuticals, Inc. has a one year low of $666.25 and a one year high of $1,211.20. The company has a market capitalization of $75.58 billion, a PE ratio of 17.02, a price-to-earnings-growth ratio of 1.61 and a beta of 0.10.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.